74 Results for "

bleeding

" in MedChemExpress (MCE) Product Catalog:
Products (74)

74 Results for "bleeding" in MCE Product Catalog:

Cat. No.: HY-N17784
CAS No.: 1610618-94-4
Peiioside A is a phenylethanoid glycoside compound that can be isolated from the leaves and stems of Callicarpa longissima. Callicarpa longissima has traditional medicinal uses for treating colds, coughs, arthritis, and bleeding, and can be used in the research of anti-inflammatory and antibacterial agents, as well as in neuroprotection-related fields.
loading...
    loading...
Cat. No.: HY-184870
CAS No.: 31621-87-1
Target:  

Others

Research Areas:  

Inflammation/Immunology

Polydioxanone is a colorless, crystalline semi-crystalline thermoplastic poly (ether-ester) bioabsorbable polymer. Polydioxanone serves as a hemostatic agent, biodegradable agent, degradant, lumen patency maintainer, as well as a temporary inducer of tracheal tissue injury and inflammation. Polydioxanone controls bone bleeding in biocompatible matrices, degrades via random hydrolytic scission and end-chain scission, with accelerated degradation occurring at pH <1.67, maintains tracheal lumen patency, and induces reversible tracheal epithelial necrosis, inflammation, fibrous tissue hyperplasia, and goblet cell hyperplasia. Polydioxanone can be used in research on bone bleeding, non-malignant tracheal stenosis, tracheobronchial stenosis, tracheobronchomalacia, and airway obstruction associated with vascular compression .
loading...
    loading...
Cat. No.: HY-P1711
CAS No.: 154447-41-3
Target:  

Inhibitory Antibodies

Research Areas:  

Cardiovascular Disease

L 366763 is a potent peptide that acts as a fibrinogen receptor antagonist, preventing collagen-induced platelet aggregation and adhesion. L 366763 inhibits platelet deposition and maintains blood flow in a baboon thrombosis model, significantly prolonging bleeding time. L 366763 has antithrombotic efficacy, whereas recombinant LAPP does not have the same effect .
loading...
    loading...
Cat. No.: HY-19517
CAS No.: 865451-66-7
Target:  

Endogenous Metabolite

Research Areas:  

Cardiovascular Disease

R1663 is a factor Xa inhibitor with anticoagulant activity. R1663 does not affect bleeding time. The pharmacodynamic effects (such as inhibition of thrombin generation) and plasma concentrations of R1663 are dose-dependent. R1663 prolongs clotting time in a concentration-dependent manner and inhibits the peak height of thrombin generation and endogenous thrombin potential .
loading...
    loading...
Cat. No.: HY-165360
CAS No.: 1225170-16-0
Target:  

Thrombin

Research Areas:  

Cardiovascular Disease

JJ1 is a selective α-thrombin inhibitor with a Ki of 0.019 μM. JJ1 directly binds to the active site of α-thrombin to block its catalytic activity. JJ1 exhibits antithrombotic effects and prolongs activated partial thromboplastin time, prothrombin time, and tail bleeding time in mice. JJ1 can be used for the research of thrombotic diseases .
loading...
    loading...
Cat. No.: HY-109091R
CAS No.: 1800046-95-0
Synonyms: GS-9876 (Standard)
Target:  

Reference Standards Syk

Research Areas:  

Inflammation/Immunology Cancer

Lanraplenib (Standard) is the analytical standard of Lanraplenib (HY-109091). This product is intended for research and analytical applications. Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib (GS-9876) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
loading...
    loading...
Cat. No.: HY-109091BR
CAS No.: 1800047-00-0
Synonyms: GS-9876 succinate (Standard)
Target:  

Reference Standards Syk

Research Areas:  

Inflammation/Immunology Cancer

Lanraplenib succinate (Standard) is the analytical standard of Lanraplenib (succinate) (HY-109091B). This product is intended for research and analytical applications. Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
loading...
    loading...
Cat. No.: HY-113958S1
Synonyms: LM-2219-d4-1
Difethialone-d4-1 (LM-2219-d4-1) is the deuterium labeled Difethialone (HY-113958). Difethialone (LM-2219) is an anticoagulant rodenticide. Difethialone shows high rodenticide activity in warfarin-sensitive and resistant strains of rats and mice. Difethialone interferes with the circulation of vitamin K in the liver, preventing the synthesis of coagulation factors, resulting in the inability of the blood to coagulate properly, ultimately causing internal bleeding and death. Difethialone can be used in studies of ecological impacts .
loading...
    loading...
Cat. No.: HY-P70191
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: LEFTY2; Left-Right Determination Factor A; Prev. TGFB4; Protein Lefty-2; Prev. EBAF; Protein Lefty-A; LEFTYA; TGF-Beta-4; LEFTA; Endometrial bleeding Associated Factor (Left-Right Determination, Factor A; Transforming Growth Factor Beta Superfamily); Endo
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-167848
CAS No.: 153345-74-5
Synonyms: XL-118
Target:  

Others

Research Areas:  

Cardiovascular Disease

DMP-728 free base (XL-118) is a highly potent and selective GPIIb/IIIa antagonist with antiplatelet and antithrombotic activities. DMP-728 free base can inhibit ADP-induced human platelet aggregation in vitro, with an IC50 of 46 nmol/L, and can significantly reduce the interaction between fibrinogen and human platelets or Binding of purified human GPIIb/IIIa receptors. DMP-728 free base exhibits dose-dependent antiplatelet effects in anesthetized mongrel dogs, effectively inhibiting ADP-induced platelet aggregation and prolonging template bleeding time .
loading...
    loading...
Cat. No.: HY-183409
CAS No.: 1941243-22-6
Synonyms: ONO-5450598
Target:  

Factor Xa

Research Areas:  

Cardiovascular Disease

ONO-7684 (ONO-5450598) is an orally active coagulation factor XIa (FXIa) inhibitor with a Ki value of 2 nM against human FXIa. ONO-7684 inhibits human FXIa in a competitive and reversible manner, reduces factor XI coagulation activity, prolongs activated partial thromboplastin time in a dose-dependent manner, and exerts no significant effects on PT/INR and the activity of related serine proteases. ONO-7684 exerts antithrombotic effects in vivo without prolonging bleeding time. ONO-7684 can be used in studies related to thromboembolic diseases .
loading...
    loading...
Cat. No.: HY-189107
CAS No.: 787548-03-2
Synonyms: INS50589 free acid
Target:  

P2Y Receptor

Research Areas:  

Cardiovascular Disease

Regrelor (INS50589 (free acid)) is a selective, reversible, and competitive P2Y12 receptor antagonist and an adenosine 5′-monophosphate derivative. Regrelor inhibits ADP (HY-W010918)-induced aggregation of human washed platelets with an IC50 of 0.016 μM. Intravenous infusion of Regrelor rapidly and dose-dependently inhibits ADP-induced platelet function, and platelet function gradually recovers after cessation of infusion. Regrelor can be used for research on P2Y12-mediated platelet function and cardiovascular regulation .
loading...
    loading...
Cat. No.: HY-118418
CAS No.: 1601-22-5
Anti-inflammatory agent 120 is an orally active non-steroidal anti-inflammatory agent. Anti-inflammatory agent 120 can be used in the research of rheumatoid arthritis, osteoarthritis, dysmenorrhea, acute gouty arthritis, ankylosing spondylitis and dementia .
loading...
    loading...
Cat. No.: HY-L136
1,525 compounds

Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation.

Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process.

MCE supplies a unique collection of 1,525 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.